Home/Filings/4/0000950170-25-037200
4//SEC Filing

Schilke Tobin 4

Accession 0000950170-25-037200

CIK 0001658247other

Filed

Mar 10, 8:00 PM ET

Accepted

Mar 11, 4:30 PM ET

Size

7.2 KB

Accession

0000950170-25-037200

Insider Transaction Report

Form 4
Period: 2025-03-10
Schilke Tobin
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2025-03-10+52,00052,000 total
  • Award

    Stock Option (Right to Buy)

    2025-03-10+80,00080,000 total
    Exercise: $33.75Exp: 2035-03-09Common Stock (80,000 underlying)
Footnotes (2)
  • [F1]The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2026.
  • [F2]The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2026, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Documents

1 file

Issuer

Crinetics Pharmaceuticals, Inc.

CIK 0001658247

Entity typeother

Related Parties

1
  • filerCIK 0001678984

Filing Metadata

Form type
4
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 4:30 PM ET
Size
7.2 KB